Skip to main content
Clinical Trials/ACTRN12612001194853
ACTRN12612001194853
Completed
Phase 3

The CNS sub-study of a randomised, double-blind, placebo-controlled, clinical trial to compare the safety and efficacy of reduced dose efavirenz (EFV) with standard dose EFV plus 2N(t)RTI in antiretroviral-naive HIV-infected individuals over 96 weeks

Kirby Institute, University of New South Wales0 sites40 target enrollmentNovember 13, 2012

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Kirby Institute, University of New South Wales
Enrollment
40
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 13, 2012
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Kirby Institute, University of New South Wales

Eligibility Criteria

Inclusion Criteria

  • All subjects entering into the main study protocol at participating centres will be eligible to enter this sub\-study

Exclusion Criteria

  • Existing neurological disease which in the opinion of the
  • investigator would be a contra\-indication to lumbar
  • puncture examination
  • CNS opportunistic infections in the past 12 weeks
  • Bacterial or viral meningitis in the past 12 weeks
  • Head injury requiring medical assessment in the past 12 weeks

Outcomes

Primary Outcomes

Not specified

Similar Trials